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Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and
limited data are available on T2DM management and the status of glycemic control in China. We assessed the
efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, and insulin for
treatment of T2DM across multiple regions in China.
Methods: This was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China.
Data from all the patients were collected between April and June, 2011.
Results: A total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs
alone (n=157,212 [65.88%]), OADs plus insulin (n=80,973 [33.93%]), or OADs plus GLP-1 receptor agonists (n=454
[0.19%]). The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated
hemoglobin (HbA1c) levels (±SD) of 7.67% (±1.58%), 8.21% (±1.91%), and 7.80% (±1.76%), respectively. Among
those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and
achievement of A1c <7.0% was related to the duration of T2DM.
Conclusions: Less than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control
decreased and insulin use increased with the duration of diabetes.
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According to a 1994 study, the incidence of type 1 dia-
betes mellitus (T1DM), also known as insulin-dependent
diabetes or childhood diabetes, in Shanghai, China is
0.72 per 100,000 residents, making it among the lowest
in the world [1]. At this incidence rate, the 13,000 T1DM
cases diagnosed annually in the United States would drop
to <500 new cases per year [1]. The prevalence of both
prediabetes and type 2 diabetes mellitus (T2DM) in
Chinese adults, however, is much higher, with a recent
national survey showing a 2008 prevalence rate of 9.7%* Correspondence: Jiln@bjmu.edu.cn
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reproduction in any medium, provided the orfor subjects ≥20 years old [2,3]. The prevalence of predia-
betes, defined by either impaired fasting glucose or
impaired glucose tolerance, is estimated to be 15.5% in
Chinese adults, which would make the total adult popula-
tion with prediabetes in China about 148.2 million people
(76.1 million men and 72.1 million women) [2]. T2DM is
estimated to affect 9.7% of the Chinese population (10.6%
of men and 8.8% of women), which would make 92.4 mil-
lion adults in China who have diabetes (50.2 million men
and 42.2 million women) [2].
Several large, well-known studies, including the United
Kingdom Prospective Diabetes Study (UKPDS), have dem-
onstrated the importance of glycemic control among pa-
tients with T2DM [4-6]. Such research has shown there is
a strong correlation between mean glycated hemoglobinhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gression of diabetic complications. Both the American
Diabetes Association and the Chinese Diabetes Society
advocate a HbA1c goal of <7.0% for individuals with
T2DM [7,8], although research has demonstrated that gly-
cemic control is difficult to achieve in China and other
Asian countries [2,3,9,10]. It has been previously shown
that approximately one half of the outpatients with T2DM
who are treated in the metropolitan medical centers
in China have inadequate glycemic control when they
are treated with oral antidiabetic drugs (OADs) alone
[11]. Currently there are several types of treatment
for T2DM, including OADs such as metformin, sulfo-
nylureas, thiazolidinediones, alpha-glucosidase inhibitors,
meglitinides, and dipeptidyl peptidase-4 (DPP-4) inhibitors;
glucagon-like peptide-1 (GLP-1) receptor agonists; and in-
sulin; and they can be used as monotherapy or in combina-
tions to arrive at the best individualized treatment plan to
achieve treatment goals [8,12,13]. Intensification of treat-
ment is often required over time as the disease progresses,
with the addition of multiple OADs and/or insulin.
A study of 7549 Chinese patients with T2DM in the
Hong Kong Diabetes Registry found that among those
treated with OADs and/or insulin, only 39.7% attained the
glycemic target of HbA1c <7% and that both long disease
duration and complexity of treatment regimens were asso-
ciated with suboptimal glycemic control [14]. The Inter-
national Diabetes Mellitus Practice Study (IDMPS) was a
5-year survey that documented changes in diabetes
treatment practice in developing regions and employed lo-
gistic regression analysis to identify factors for achieving
HbA1c <7% in 11,799 patients, 1898 with T1DM and 9901
with T2DM; patients were recruited from 17 countries in
Eastern Europe, Asia, Latin America, and Africa [15]. That
study revealed that only 20%-30% of patients achieved the
goal of HbA1c <7%. An additional publication of results
from IDMPS reported that education increased the use of
insulin and improved self-care performance of patients
with T2DM, and that it resulted in lower rates of chronic
complications while significantly increasing the percentage
of individuals patients who achieved HbA1c <7% [16].
Although the population with T2DM in China is close
to 100 million patients, limited data are available on the
management of those individuals and the status of gly-
cemic control within that nation. The objective of this
noninterventional study was to evaluate the characteris-
tics, glycemic status, and treatment strategies used in pa-
tients with T2DM across China treated with oral agents
alone or in conjunction with or GLP-1 receptor agonists.
Methods
Study design
This was a multicenter, cross-sectional survey of outpa-
tients with T2DM conducted in 606 hospitals across China,representing every region of the mainland other than Tibet.
Each of the patients provided written informed consent.
All of the data were collected between April and June,
2011. Prior to initiation of this study, the survey used (see
Additional file 1) was approved by the Ethics Committee
of Chinese PLA General Hospital, and was reviewed and
accepted by all the participating hospitals.
Each day during the study period, the first 7 patients
who entered a participating facility and met the eligibil-
ity criteria were invited to participate. The study investi-
gators conducted the surveys by communicating directly
with the patients, and interviews were performed by
study investigators to complete the survey. All laboratory
evaluations were performed in the local hospitals where
the interviews were conducted.
The survey captured general information about each
patient, including gender, height, weight, blood pressure,
and lipid profile. Laboratory data on HbA1c, fasting
plasma glucose (FPG), and postprandial plasma glucose
(PPG) levels were collected. Specific information about the
treatments used for the management of their T2DM were
identified, including the use of OADs (including DPP-4 in-
hibitors), GLP-1 receptor agonists, and different types of
insulin, as well as combinations of OADs and insulin and
the combination of OADs and a GLP-1 receptor agonist.
Patients were also required to report if they were diag-
nosed with any concomitant diseases or diabetes compli-
cations, including hypertension, coronary heart disease,
dyslipidemia, cerebrovascular disease, diabetic retinopathy,
diabetic neuropathy, diabetic nephropathy, diabetes-related
foot ulcers, and others (see Additional file 1).
Inclusion criteria
Outpatients with T2DM being treated with OADs alone,
OADs combined with insulin, or OADs combined with
GLP-1 receptor agonists were eligible to participate in this
study if they were at least 18 years of age, had at least one
previous outpatient medical record pertaining to diabetes,
and had resided within a local area for at least 6 consecu-
tive months prior to initiation of the study.
Exclusion criteria
Individuals could not participate in this study if they had
secondary diabetes [17] or were only receiving treatment
with insulin. Patients were excluded if they were not
receiving OAD monotherapy, OADs in combination with
insulin, or OADs in combination with GLP-1 receptor
agonists. Other individuals who were excluded were
patients with T1DM, inpatients, those receiving thera-
peutic lifestyle changes or Chinese herbal medicine
only, those who were pregnant or breast-feeding, and
those who were either mentally incapable or for other
reasons unable to adequately understand or participate
in the study.
Table 1 Baseline characteristics
Characteristic Male Female All
Mean±SD
Age, yrs 58.39±12.01 59.09±11.32 58.72±11.69
BMI, kg/m2 24.47±2.92 24.38±3.41 24.43±3.16
Duration of diabetes, yr 5.43±5.16 5.71±5.40 5.57±5.28
HbA1c, % 7.90±1.73 7.80±1.71 7.85±1.72
FPG, mmol/L 8.12±2.40 8.02±2.39 8.07±2.39
2hPPG, mmol/L 11.26±3.64 11.12±3.63 11.19±3.64
SBP, mmHg 132.35±14.79 131.39±15.50 131.89±15.14
DBP, mmHg 81.86±11.00 80.10±11.05 81.02±11.06
Triglycerides, mmol/L 2.22±1.65 2.10±1.46 2.16±1.56
Total cholesterol, mmol/L 4.71±1.48 4.75±1.48 4.73±1.48
LDL, mmol/L 2.92±1.16 2.92±1.16 2.92±1.16
Reason for insulin initiation,
n (%)
OAD ineffective 33341 (77.18) 29525 (78.17) 62866 (77.64)
Complication 5531 (12.80) 4862 (12.87) 10393 (12.84)
Patient requests 3041 (7.04) 2382 (6.31) 5423 (6.70)
Other reason 1288 (2.98) 1003 (2.65) 2291 (2.82)
Complications and
comorbidities, n (%)
Hypertension 41400 (33.25) 38194 (33.46) 79594 (33.35)
Coronary heart disease 12918 (10.38) 13125 (11.50) 26043 (10.91)
Dyslipidemia 25222 (20.26) 21712 (19.02) 46934 (19.67)
Cerebrovascular disease 6552 (5.26) 5526 (4.84) 12078 (5.06)
Diabetic retinopathy 9799 (7.87) 10046 (8.80) 19845 (8.32)
Diabetic neuropathy 13211 (10.61) 12930 (11.33) 26141 (10.95)
Diabetic nephropathy 7001 (5.62) 5702 (5.00) 12703 (5.32)
Diabetic foot 1380 (1.11) 1087 (0.95) 2467 (1.03)
Others 2438 (1.96) 2469 (2.16) 4907 (2.06)
2hPPG, 2-hr postprandial plasma glucose; BMI, body mass index; DBP, diastolic
blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LDL,
low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.
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Statistical analyses were conducted using SAS version
9.1.3 (SAS Institute, Cary, NC, USA). Descriptive statistics
were used to characterize the data in the study, including
calculations of means and standard deviations. Com-
parisons were statistically analyzed using t-tests and chi-
squared tests, and a logistic regression analysis of patient
characteristics and treatment regimens was conducted.
Results
A total of 238,656 subjects with T2DM were surveyed
and 238,639 were included in the final analyses. Seven-
teen subjects who completed the survey but had re-
ceived monotherapy with GLP-1 receptor agonists were
excluded. Demographic information and baseline char-
acteristics of the study population are shown in Table 1.
Table 2 presents the clinical characteristics of the pa-
tients, including their treatment regimens and HbA1c
levels. Mean HbA1c did not vary by BMI at baseline;
however, a slightly higher percentage of patients with
BMI <24 kg/m2 achieved HbA1c <7.0% than patients
with BMI ≥24 kg/m2. Mean HbA1c was significantly
lower and HbA1c goal attainment was significantly higher
among patients who performed self-monitored blood glu-
cose (SMBG) compared to those who did not. Compared
to those without diabetes complications or concomitant
disease, individuals who had them had higher HbA1c levels
(and a lower rate of HbA1c goal achievement (Table 2).
Mean HbA1c and HbA1c goal attainment varied among
treatment groups. Mean HbA1c was lower and the propor-
tion of patients who achieved HbA1c <7.0% was higher
among patients receiving OADs only and patients receiv-
ing OADs plus GLP-1 receptor agonists compared to pa-
tients receiving insulin plus OADs (Table 2). In fact, mean
HbA1c increased and HbA1c goal achievement decreased
with increasing numbers of OADs used. Among patients
receiving OADs and insulin, mean HbA1c was lowest
among patients receiving basal insulin alone and highest
among patients receiving basal-bolus therapy. HbA1c goal
achievement followed the same trend. However, diabetes
duration was shorter among patients using OADs only
(4.76 years) and longer among patients using OADs and
insulin (7.12 years; p < 0.0001). Diabetes duration increased
with the number of OADs used and increased as insulin
therapy intensified (Table 2).
The association between diabetes duration, diabetes
complications and concomitant diseases, treatment, and
glycemic control is explored in more detail in Table 3.
Regardless of treatment used, mean HbA1c generally in-
creased with the duration of diabetes, as also shown in
Figure 1. Similarly, HbA1c goal achievement generally
decreased with the duration of diabetes (Table 3). The
exception to both these trends occurred among individuals
with a diabetes duration of <1 year, and the prevalence ofconcomitant diseases and complications also increased
with diabetes duration.
Trends in treatment with diabetes duration were also
observed. The use of oral agents alone decreased with
diabetes duration (from 72.58% in individuals with a dur-
ation of <1 year to 47.57% in individuals with a diabetes
duration of ≥10 years). Corresponding increases in OAD
plus insulin use were also observed. Among individuals
with a diabetes duration of <1 year, 27.27% used OADs in
combination with insulin, while 52.28% of individuals
with a diabetes duration of ≥10 years used a combination
of OADs and insulin (Table 3).
The survey also captured reasons why insulin was
added to the OAD regimens (data not shown). OADs
were deemed ineffective (62,866/80,973; 77.64%), there
Table 2 Clinical characteristics
Characteristic Diabetes duration (yrs) Age (yrs) HbA1c (%) Patients with HbA1c <7.0%
n (%) Mean±SD n (%)
No. of patients 238,639 (100) 5.57±5.28 58.72±11.69 7.85±1.72 75,829 (31.78)
BMI
<24 kg/m2 110,283 (46.21) 5.44±5.26 58.43±11.73 7.85±1.79 36,507 (33.10)
≥24 kg/m2 128,356 (53.79) 5.67±5.29 58.98±11.66 7.86±1.67 39,322 (30.64)
P value <0.0001 <0.0001 0.2848 <0.0001
Treatment regimen
OAD only 157,212 (65.88) 4.76±4.65 58.16±11.52 7.67±1.58 54,438 (34.63)
1 OAD 58,028 (24.32) 4.38±4.95 57.45±12.08 7.65±1.69 21,834 (37.63)
2 OADs 80,113 (33.57) 4.74±4.34 58.35±11.21 7.66±1.53 26,942 (33.63)
≥3 OADs 19,071 (7.99) 6.01±4.71 59.56±10.89 7.75±1.49 5662 (29.69)
P value <0.0001 <0.0001 <0.0001 <0.0001
OAD + insulin 80,973 (33.93) 7.12±6.04 59.85±11.92 8.21±1.91 21,227 (26.21)
Prandial 6243 (2.62) 6.30±5.91 58.83±12.49 8.14±2.06 1745 (27.95)
Basal 13,816 (5.79) 6.58±5.54 59.13±11.97 7.99±1.81 4251 (30.77)
Premixes 53,122 (22.26) 7.20±6.02 60.24±11.66 8.18±1.86 13,787 (25.95)
Basal-bolus 6411 (2.69) 8.12±6.87 58.90±13.02 8.89±2.25 1143 (17.83)
Others 1381 (0.58) 8.70±6.75 60.70±12.57 8.45±2.00 301 (21.80)
P value <0.0001 <0.0001 <0.0001 <0.0001
OAD + GLP-1 RA 454 (0.19) 5.39±4.46 53.12±12.90 7.80±1.76 164 (36.12)
P valuea <0.0001 <0.0001 <0.0001 <0.0001
SMBG
Yes 90,557 (37.95) 5.86±5.25 58.96±11.46 7.68±1.62 31,979 (35.31)
No 148,082 (62.05) 5.39±5.29 58.58±11.83 7.96±1.77 43,850 (29.61)
P value <0.0001 <0.0001 <0.0001 <0.0001
Concomitant disease/complications
Yes 124,182 (52.04) 6.82±5.70 61.13±11.36 7.95±1.77 36,947 (29.75)
No 81,405 (34.11) 4.09±4.39 55.30±11.38 7.71±1.69 29,254 (35.94)
Don’t know 33,052 (13.85) 4.47±4.39 58.09±11.48 7.82±1.58 9,628 (29.13)
P value <0.0001 <0.0001 <0.0001 <0.0001
aComparison among different treatment regimens, ie, OAD only, OAD + insulin, OAD + GLP-1 RA.
P values were calculated using chi-square analysis and ANOVA as appropriate.
BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; OAD, oral antidiabetes drug; SD, standard deviation;
SMBG, self-monitored blood glucose.









OAD (%)b Insulin + OAD
(%)b
GLP-1 RA + OAD
(%)b
<1 36,337 (15.22) 8.12±1.99 12,663 (34.85) 11,007 (30.29) 26,372 (72.58) 9909 (27.27) 56 (0.15)
≥1-5 102,550 (42.97) 7.66±1.61 45,533 (44.40) 36,331 (35.43) 75,459 (73.58) 26,896 (26.23) 195 (0.19)
≥5-10 55,744 (23.36) 7.84±1.66 34,374 (61.67) 16,915 (30.34) 34,446 (61.79) 21,159 (37.96) 139 (0.25)
≥10 44,003 (18.44) 8.09±1.76 31,607 (71.83) 11,575 (26.31) 20,933 (47.57) 23,006 (52.28) 64 (0.15)
P valuec <0.0001 <0.0001 <0.0001 <0.0001 NS NS
aPercentage of patients among the full population; bPercentage of patients among the patients with particular diabetes duration; cANOVA and chi-square test
were used as appropriate.
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; NS = not significant; OAD, oral antidiabetes drug; SD, standard deviation.
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Figure 1 Mean HbA1c and mean percentage of patients achieving HbA1c <7.0% by duration of type 2 diabetes. HbA1c: glycated
hemoglobin, T2DM: type 2 diabetes mellitus.
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sons, not specified. Among the small numbers of patients
who used GLP-1 receptor agonists with OADs, frequency
of use did not appear to vary by diabetes duration.
Table 4 presents data on the type of insulin used
among individuals reporting combination OAD and in-
sulin use by the duration of diabetes. Overall, approxi-
mately two thirds (52,643/80,308, 65.6%) of OAD plus
insulin users used insulin premixes. The proportion of
insulin premix use was relatively consistent regardless of
the duration of diabetes, ranging from 62.91% to 67.50%
with no discernible pattern across the duration of the
disease. No overt trends in prandial or basal insulin use
by diabetes duration were observed, although there was
a small increase in the use of basal-bolus therapy with
increasing diabetes duration. A logistic regression ana-
lysis revealed the several characteristics and treatmentTable 4 Insulin use in OAD plus insulin group, by insulin trea
Insulin treatment duration (yrs) n (%)a Prandial, n (%)b Bas
<1 21,145 1987 337
(26.33) (9.40) (15.9
≥1-5 27,617 2171 499
(34.39) (7.86) (18.0
≥5-10 18,504 1198 314
(23.04) (6.47) (17.0
≥10 13,042 (16.24) 834 (6.39) 2,22
Totalc 80,308 6190 13,7
P valued <0.0001 NS
aPercentage of patients among the full population; bPercentage of patients among
duration were missing for 665 patients using insulin therapy; dChi-square test was u
insulin treatment duration.
NS = not significant.regimens that were associated with patients attaining
HbA1c <7.0% (Table 5).
Discussion
Results from this large-scale survey of almost 240,000
patients throughout China demonstrated that, overall, pa-
tients with T2DM do not meet the treatment guideline set
by the American Diabetes Association (ADA) and the
Chinese Medical Society of an HbA1c <7%. More specif-
ically, less than one third of individuals with type 2 dia-
betes using OADs, either alone or in combination with
insulin or GLP-1 receptor agonists, achieved glycemic
control as defined by HbA1c <7.0%. These results are
comparable to those obtained in an earlier study that
reported 39.7% of patients treated with OADs and/or
insulin achieved HbA1c <7% [14]. Because our objective
was to characterize Chinese patients receiving OADs fortment duration
al, n (%)b Basal-bolus, n (%)b Premixes, n (%)b Others, n (%)b
6 1623 13,825 334
7) (7.68) (65.37) (1.58)
2 1711 18,334 409
8) (6.20) (66.38) (1.48)
8 1561 12,280 317
1) (8.44) (66.37) (1.71)
3 (17.04) 1471 (11.28) 8204 (62.91) 310 (2.38)
39 6366 52,643 1370
NS NS NS
the patients with particular insulin treatment duration; cData on diabetes
sed to compare the percentage of patients in different insulin regimens by
Table 5 Logistic regression analysis for the patients
achieving HbA1c <7.0%
Characteristics Wald X2 P value Odds ratio 95% CI
Age 163.1497 <0.0001 1.005 1.004-1.006
Sex male 187.2576 <0.0001 0.885 0.870-0.901
Duration of diabetes 468.9675 <0.0001 0.979 0.977-0.981
BMI 101.4330 <0.0001 0.986 0.983-0.988
No complications 321.8294 <0.0001 1.203 1.179-1.228
SMBG 1251.9703 <0.0001 1.387 1.362-1.412
Treatment regimen
(vs OAD+insulin)
OAD+GLP1 22.6761 <0.0001 1.600 1.319-1.941
1 OAD 1663.4200 <0.0001 1.649 1.610-1.690
2 OADs 804.4268 <0.0001 1.377 1.347-1.408
≥3 OADs 88.2917 <0.0001 1.183 1.142-1.225
Results interpretation: Patients who are elderly, female, with shorter duration
of diabetes, less BMI, without complications, performed SMBG recently, treated
with OAD only or OAD+GLP1 were more likely to attain the HbA1c targets.
BMI, body mass index; CI, confidence interval; GLP-1 RA, glucagon-like
peptide-1 receptor agonist; OAD, oral antidiabetes drug; SMBG, self-monitored
blood glucose.
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treated with diet and lifestyle interventions alone or insulin
without oral agents.
Glycemic control appeared to be greater among individ-
uals treated with only OADs compared to those receiving
more intensive therapy with OADs in combination with
insulin. This, however, might be a function of duration of
disease. Similarly, among patients using OADs in combin-
ation with insulin, glycemic control appeared to be greater
among patients receiving prandial insulin alone, basal insu-
lin alone, or insulin premixes compared with basal-bolus
therapy, a more intensive intervention. This difference may
represent an attempt to improve glycemic control in pa-
tients at higher HbA1c levels through the addition of more
intensive insulin therapy.
It is also likely that the difference in glycemic control
may result from differences in disease severity. This hy-
pothesis is supported by several findings in our study.
First, mean HbA1c generally increased and HbA1c goal
achievement generally decreased with increasing dia-
betes duration. The exception in this trend occurred in
patients with a diabetes duration of less than 1 year, pos-
sibly because the optimal treatment regimen had not yet
been identified due to the recentness of the diagnosis.
Both the association between glycemic control and dia-
betes duration, and the differences in glycemic control
between individuals using OADs and those using insulin,
have been reported in other observational studies, in-
cluding a recent study of Chinese individuals with type 2
diabetes in the Jiangsu province [18]. It also should be
noted that differences in glycemic control among studygroups were relatively small, suggesting that treatment
was adjusted to accommodate the progressive hypergly-
cemia seen with advancing diabetes.
Because diabetes is a progressive disease, patients who
have had a longer duration of diabetes are likely to have
reduced beta-cell function and require more intensive
therapy compared to patients with more recently diag-
nosed disease. In our study, patients using OADs plus
insulin therapy had a longer history of diabetes than pa-
tients using OADs alone. This trend was apparent even
among patients using only OADs: patients using 3 or
more OADs had a longer duration of diabetes than
patients using only one OAD.
The inverse association between disease severity and
glycemic control is also supported by the prevalence of
concomitant diseases and diabetes complications in the
study. Patients using OADs plus insulin typically had a
higher prevalence of complications and concomitant dis-
ease than patients using only OADs. Not surprisingly,
the prevalence of complications and concomitant disease
also increased with diabetes duration, a finding indica-
tive of the association between duration of hypergly-
cemia and likelihood of adverse vascular effects.
Our study also demonstrated the positive impact of
SMBG on glycemic control. Patients who performed
SMBG had a lower mean HbA1c and a greater percentage
of HbA1c goal achievement compared to patients who did
not. Interestingly, patients who performed SMBG had a
longer history of diabetes compared with those who did
not. This may be due to the increased need for SMBG with
the use of more intensive insulin regimens utilized by pa-
tients with more advanced disease. Nonetheless, these find-
ings suggest that initiating SMBG may be one way to
overcome the loss of diabetes control with diabetes pro-
gression despite the increased intensity of treatment.
This study has several limitations. First, this is a descrip-
tive analysis of the results from patient interviews. No at-
tempt was made to control for confounding factors, and
statistical analyses of the data were limited. Results col-
lected from patient interviews and self-reports are subject
to bias; however, patient interviews are the most practical
way of obtaining such information in China [18].
Conclusions
This is one of the largest studies conducted among the
Chinese population with T2DM, and the data obtained
during this study reveal several clinically important
findings. The majority of patients with type 2 dia-
betes receiving oral agents did not achieve the goal
of HbA1c <7.0%, indicating that substantial improve-
ments in treatment are still necessary. In fact, among
all three patient groups, those receiving OADs, OADs in
combination with GLP-1 receptor agonists, and OADs in
combination with insulin, only 26%-38% achieved the goal
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adjusting or changing treatments earlier or more fre-
quently may enable patients to achieve even better gly-
cemic control.
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